What is the recommended treatment and dosages for recurrent aphthous stomatitis in an adult?

Treatment for Recurrent Aphthous Stomatitis

For recurrent aphthous stomatitis, start with topical high-potency corticosteroids as first-line therapy: use dexamethasone mouth rinse 0.1 mg/ml for multiple or hard-to-reach ulcers, or clobetasol gel/ointment 0.05% for localized, accessible lesions.

Treatment Algorithm Based on Severity

Mild to Moderate Disease (First-Line Topical Therapy)

Topical Corticosteroids 1:

• Dexamethasone mouth rinse 0.1 mg/ml: Use when multiple oral cavity locations are involved or ulcerations are difficult to reach
• Clobetasol gel or ointment 0.05%: Use for limited locations and easily accessible ulcers
• These are the recommended first-line agents based on expert consensus

Adjunctive Topical Options 1, 2, 3:

• Amlexanox 5% oral paste: For moderate pain relief (topical NSAID)
• Doxycycline topical: Network meta-analysis showed this was the most efficacious intervention for promoting healing 3
• Hyaluronic acid: Demonstrated favorable short-term efficacy with good safety profile 4
• Viscous lidocaine 2%: For symptomatic pain relief before meals 1, 5

Basic Oral Care 1:

• Sodium bicarbonate-containing mouthwash (non-alcoholic): 4-6 times daily for prevention
• Increase frequency up to hourly during active outbreaks

Refractory Disease (Escalation to Intralesional Therapy)

If ulcers do not resolve with topical therapy 1:

• Intralesional triamcinolone injection: Weekly injections, total dose 28 mg
• Continue concurrent topical clobetasol gel/ointment 0.05%
• Requires consultation with oral medicine specialist

Severe or Highly Symptomatic Disease (Systemic Therapy)

For continuous aggressive outbreaks, major aphthae, or recurrent ulcers 1, 2:

Systemic Corticosteroids 1:

• Prednisone/prednisolone 30-60 mg daily (or 1 mg/kg) for 1 week
• Followed by dose tapering over the second week
• Use as initial therapy to bring symptoms under control quickly

Alternative Systemic Agents for Refractory Cases:

• Colchicine 0.5 mg three times daily 6: However, note that 23-45% experience treatment interruption due to gastrointestinal side effects
• Clofazimine 100 mg daily for 30 days, then 100 mg every other day 6: 17-44% of patients had no further aphthous episodes (superior to colchicine)
• Thalidomide 7, 2, 4: Effective for severe refractory cases (25 mg daily showed dramatic response), but reserved for selected cases due to adverse effects and restricted availability
• Roflumilast 8: Recent 2024 study showed 88% reduction in flare-ups and 94% reduction in oral ulcers; well-tolerated at low doses with manageable side effects (primarily headache and GI disturbances)

Pain Management Strategy

Mild Pain 1:

• Viscous lidocaine 2% mouthwash
• Coating agents

Moderate Pain 1:

• Amlexanox 5% oral paste (topical NSAID)
• If NSAIDs not tolerated: acetaminophen as maintenance therapy

Severe Pain 1:

• Immediate-release oral opioids
• Fast-acting fentanyl 50 μg nasal spray for short-term relief (e.g., before meals)
• Consider transdermal or intranasal routes if oral administration is complicated

Important Clinical Considerations

Critical Pitfalls to Avoid:

• The provided guidelines [1-1] are primarily for mTOR inhibitor-associated stomatitis in cancer patients, not idiopathic recurrent aphthous stomatitis. However, the treatment principles and dosing regimens are applicable and represent expert consensus.
• Do not jump to systemic therapy without trying topical corticosteroids first—they are effective and have minimal systemic absorption
• Systemic corticosteroids should be reserved for truly severe or refractory cases due to side effect profile
• When prescribing colchicine, warn patients about high likelihood of GI side effects

Evidence Quality Note: The most recent high-quality evidence 4 from a 2026 umbrella review confirms that topical corticosteroids and low-level laser therapy consistently reduce pain and shorten healing time, though evidence for recurrence prevention is limited. The 2024 roflumilast study 8 and 2023 network meta-analysis 3 provide the most current data supporting doxycycline topical therapy for healing and roflumilast as an emerging systemic option with favorable tolerability.

Treatment Duration: Most topical therapies should be continued throughout the outbreak. Systemic therapies typically require 6 months of treatment for sustained benefit 6, though acute severe episodes may respond to shorter corticosteroid courses.